Plato Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Plato Investment Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.72M	Hold	3,519	–	–	0.18%	125
2025 Q4	$2.73M	Buy	3,519 +33	+0.9%	+$22.4K	0.18%	120
2025 Q3	$1.95M	Sell	3,486 -293	-8%	-$166K	0.13%	172
2025 Q2	$1.98M	Buy	3,779 +2	+0.1%	+$1.12K	0.15%	154
2025 Q1	$2.42M	Buy	3,777 +1,116	+42%	+$768K	0.2%	121
2024 Q4	$1.9M	Buy	2,661 +44	+2%	+$36.9K	0.14%	159
2024 Q3	$2.75M	Buy	2,617 +79	+3%	+$87.9K	0.22%	113
2024 Q2	$2.67M	Buy	2,538 +144	+6%	+$140K	0.25%	94
2024 Q1	$2.3M	Buy	2,394 +2,271	+1,846%	+$2.16M	0.24%	109
2023 Q4	$108K	Buy	+123	New	+$101K	0.13%	150

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Plato Investment Management's REGN Position: Q1 2026 in Review

Plato Investment Management held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 3,519 shares worth $2.72M. The position accounts for 0.18% of the portfolio, ranked #125.

Plato Investment Management first reported a position in REGN in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.75M in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Plato Investment Management held 3,519 shares of Regeneron Pharmaceuticals worth $2.72M as of Q1 2026.
Plato Investment Management left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
Regeneron Pharmaceuticals made up 0.18% of Plato Investment Management's portfolio in Q1 2026, its #125 holding.
Plato Investment Management first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Plato Investment Management's Regeneron Pharmaceuticals position peaked at $2.75M in Q3 2024.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Plato Investment Management's 13F filing for Q1 2026, filed 5 May 2026.